All In Biotech

Drug Trial Radar · NCT03467425

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting

Last checked: Nov 19, 2026Latest source record: Sep 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 3,109 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,109

Actual

Start

Apr 11, 2018

Primary completion

Oct 10, 2019

Study completion Oct 10, 2019

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA relative to non-ELLIPTA Multiple Inhaler Triple Therapies (MITT) for Chronic Obstructive Pulmonary Disease (COPD) control within the usual clinical practice setting. The study will be conducted once TRELEGY ELLIPTA has been approved in the countries in which the study will be conducted and is available commercially. This is a randomized, open-label, effectiveness, phase 4 study of 24 weeks' duration in COPD subjects to evaluate TRELEGY ELLIPTA (fluticasone furoate \[FF\]/vilanterol \[VI\]/umeclidinium bromide \[UMEC\]: 100 microgram \[mcg\]/62.5 mcg/25 mcg) inhalation powder taken once daily using a single ELLIPTA inhaler compared with any non-ELLIPTA MITT in the usual care setting. Effectiveness of TRELEGY ELLIPTA will be assessed by comparing proportion of COPD Assessment Test (CAT) responders at Week 24 between two treatment groups. TRELEGY and ELLIPTA are trademarks of GlaxoSmithKline (GSK) group of companies. The study will enroll approximately 3000 subjects.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • FF/UMEC/VIDrug

    FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.

  • Inhaled CorticosteroidDrug

    Inhaled Corticosteroid (ICS) as prescribed by the physician.

  • LAMADrug

    LAMA as prescribed by the physician.

  • LABADrug

    LABA as prescribed by the physician.

  • COPD rescue medicationsDrug

    Rescue medications for COPD will be prescribed and obtained according to usual practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Responders and Non-responders Based on the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 24 and Number of Participants With Imputed CAT Score at Week 24Time frame: At Week 24

Locations

143 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Deggendorf, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Aschaffenburg, Bavaria, Germany

  • GSK Investigational Site

    Dachau, Bavaria, Germany

  • GSK Investigational Site

    Garmisch-Partenirchen, Bavaria, Germany

  • GSK Investigational Site

    Wallerfing, Bavaria, Germany

  • GSK Investigational Site

    Cottbus, Brandenburg, Germany

  • GSK Investigational Site

    Fürstenwalde, Brandenburg, Germany

  • GSK Investigational Site

    Potsdam, Brandenburg, Germany

  • GSK Investigational Site

    Potsdam, Brandenburg, Germany

  • GSK Investigational Site

    Rüdersdorf, Brandenburg, Germany

  • GSK Investigational Site

    Darmstadt, Hesse, Germany

  • GSK Investigational Site

    Frankfurt am Main, Hesse, Germany

  • GSK Investigational Site

    Frankfurt am Main, Hesse, Germany

  • GSK Investigational Site

    Fulda, Hesse, Germany

  • GSK Investigational Site

    Marburg, Hesse, Germany

  • GSK Investigational Site

    Rodgau, Hesse, Germany

  • GSK Investigational Site

    Rüsselsheim am Main, Hesse, Germany

  • GSK Investigational Site

    Hanover, Lower Saxony, Germany

  • GSK Investigational Site

    Hanover, Lower Saxony, Germany

  • GSK Investigational Site

    Peine, Lower Saxony, Germany

  • GSK Investigational Site

    Wardenburg, Lower Saxony, Germany

  • GSK Investigational Site

    Bergisch Gladbach, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Bonn, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Cologne, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Essen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Essen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Gelsenkirchen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Rheine, North Rhine-Westphalia, Germany

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.